NICE does not recommend Saxenda as a treatment for obesity. - Novo Nordisk
Related news and insights
Novo Nordisk announced that the FDA has approved Wegovy (the brand name for once-weekly semaglutide 2.4 mg injection in the US) for chronic weight management. Wegovy is indicated as an adjunct to diet and exercise for chronic weight management in adults with obesity (initial BMI greater than 30 kg/m2) or overweight (initial BMI greater than 27 kg/m2) with at least one weight-related comorbidity.
Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has recommended that the use of Saxenda (liraglutide) is expanded for the treatment of obesity in adolescents aged 12–17 years.
New results from the STEP phase IIIa clinical trial programme demonstrated weight loss with investigational treatment of once-weekly subcutaneous semaglutide 2.4 mg versus placebo.